NCT05621707Active, not recruitingPhase 2
Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)
A Phase 2 Trial of Concurrent Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Patients With Locally-advanced Esophageal Squamous Cell Cancer
Source: ClinicalTrials.gov · Last updated 2 Feb 2026
Brief summary (registry, in English)
This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of non-operative Locally Advanced Esophageal Cancer . The purpose of this study was to evaluate the efficacy and safety of Concurrent Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Patients With Locally-advanced Esophageal Squamous Cell Cancer.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 5 Nov 2022
- Start date
- 2 Nov 2022
- Primary completion date
- Oct 2026
- Lead sponsor
- Shanghai Chest Hospital
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT05621707
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 50
- From 2 Nov 2022 to the primary completion date, Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior thoracic irradiation, chemotherapy, or lobectomy
Other illness
- Known malignancy diagnosed or require active treatment in the last 5 years, except for cancers that can be cured by surgery including cervical cancer in situ, basal or squamous cell skin cancer, breast ductal carcinoma in situ, localized prostate cancer;
- Known diseases or conditions that are contraindicated for radiotherapy or surgery;
- Allergy to the research medications;
- Diagnosis of autoimmune disease or history of chronic autoimmune disease
- Patients with comorbidities (chronic pulmonary disease, poorly controlled hypertension, unstable angina, myocardial infarction within 6 months, unstable mental disorders requiring therapy).
Other
- Distant metastasis;
- Pregnant women or women preparing for pregnancy;
- Absence of informed consent because of psychological, family, social and other factors;
Who the study is looking for
- Aged ≥ 18 years at the time of screening.
- Histologically confirmed squamous cell carcinoma;
- Locally-advanced ,medical inoperability, technical irresectability, or patient refusal to surgery;
- Eastern Cooperative Oncology Group (ECOG) performance status:0-2;
- Able to eat a semi-liquid diet;
- Less than 20% weight loss within 6 months;
- Adequate hepatic function, renal function, hematologic function and coagulation function;
- Documented informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Chest Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.